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ABSTRACT
Introduction. Vector-based intracerebral gene therapies are being used to treat specific neurodegenerative conditions such as 
Parkinson’s Disease (PD). This review presents a basis for central nervous system (CNS) gene therapy treatments of neurodegene-
rative diseases such as PD, as well as the need for novel skill sets and health delivery strategies within the clinical neurosciences 
(neurology and neurosurgery) to meet future demand for such therapies. 
State of the art. Preclinical vector-based gene therapy approaches have been translated into clinical trials for PD and other 
neurodegenerative conditions. Unfortunately, such trials, and parallel efforts using other therapeutics, have yet to provide 
a breakthrough. Image-guided convection enhanced delivery (CED) optimises the parenchymal distribution of gene therapies 
applied within the CNS, and may ultimately provide such a breakthrough. 
Clinical implications. Currently, image-guided CED and gene therapy are not part of training programmes for most neuro-
surgeons and neurologists. As a result, few medical centres and hospitals have sufficiently experienced teams to participate in 
gene transfer clinical trials for PD or other neurological conditions. If CNS gene therapies prove to be efficacious for PD and/or 
other conditions, the demand for such treatments will overwhelm the available number of experienced clinical neuroscience 
teams and treatment centres.
Future directions. Expanded indications and demand for CNS gene therapies will require a worldwide educational effort to 
supplement the training of clinical neuroscience practitioners. Initially, a limited number of Centres of Excellence will need to 
establish relevant educational training requirements and best practice for such therapeutic approaches. Advanced technolo-
gies, including robotics and artificial intelligence, are especially germane in this regard, and will expand the treatment team’s 
capabilities while assisting in the safe and timely care of those afflicted. 
Key words: gene therapy, convection-enhanced delivery, Parkinson’s Disease, clinical neuroscience education, robotics, artificial 
intelligence 
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Introduction
The application of novel biological and biophysical kno-
wledge to therapeutic and technological innovations in 
medicine, especially since around 1990, has provided bre-
akthrough interventions for a variety of neurological con-
ditions previously considered to be untreatable or incapable 
of being completely treated. Historical indirect (systemic) 
attempts to provide therapeutic molecular compounds to 
the central nervous system (CNS) have been restricted by 
the presence of the blood-brain-barrier (BBB). More direct 
routes of drug delivery, including drug distribution via ce-
rebrospinal fluid (by lumbar puncture, subarachnoid, drug 
polymer, or intraventricular delivery) is limited by diffusive 
properties and non-targeted distribution [1–4]. While provi-
ding drug to a targeted CNS site, direct surgical placement of 
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drug-impregnated polymers for treatment of malignant CNS 
tumour remains limited by diffusional forces at the polymer 
edge (i.e. the drug only penetrates tissue millimetres from 
the polymer edge with a steep drop-off in concentration) and 
tissue injury at the site of placement. 
Recently, the successful development of new molecular 
agents, device innovations, and improved neurosurgical 
techniques have helped ‘unlock’ the CNS to direct delivery via 
infusion, providing a route for the more effective treatment 
of specific neurological maladies. Consequently, direct intra-
cerebral delivery strategies to the CNS, ones that circumvent 
the BBB through intraparenchymal CNS infusions, are being 
employed. For conditions requiring parenchymal penetration 
of the therapeutic agent, especially in treating distinct, focal 
targets, direct intraparenchymal delivery is preferred.
Today, more effective direct CNS intraparenchymal distri-
bution of drugs and biologics is being achieved via convection-
-enhanced delivery (CED) methods, first developed in the early 
1990s [5, 6]. CED uses a constant pressure gradient-dependent 
bulk flow within the extracellular fluid of the CNS derived from 
an external pump. This drives both small and large molecular 
species (including macromolecules and viruses [7]) within the 
infusate, well beyond the limits of simple diffusion from the 
site of injection (multiple centimetres rather than millimetres). 
Bulk flow associated with CED, therefore, transports the in-
fusate homogeneously within a volume of distribution (Vd) 
that is dependent on the infusion volume (Vi) and the specific 
tissue characteristics of the target parenchymal volume. CED 
provides a steep concentration drop at the advancing margin 
of the convected infusate (Fig. 1). 
Such a distribution strategy is ideal for covering a specific 
parenchymal volume with a homogenous concentration of 
a therapeutic drug, while limiting such concentrations within 
the surrounding tissue. Usually, intraparenchymal injection 
strategies without CED limit their distribution to the end of 
the injection needle or cannula, within a small cavity, and 
tend to lose the rest of their Vi to reflux outside the paren-
chyma, and often into the subarachnoid space. Without or 
with CED, distribution beyond the infusate margin continues 
over time, as a result of a constant physiological bulk flow 
induced by the ‘perivascular pump’ mechanism [8], as well 
as by diffusion. 
Iterative improvements in convective delivery methodo-
logy [9–11], delivery cannula designs [12, 13], the safe use of 
contrast co-infusions for real-time parenchymal CED visuali-
sations [14–17], and intraoperative magnetic resonance ima-
ging (iMRI) [18], have catalysed the development of this uni-
que intracerebral therapeutic direct delivery platform [17, 19], 
with initial applications focused on neuro-oncology [20–23] 
and certain inherited neurometabolic disorders [24, 25]. 
With advances made in gene therapies for treating specific 
human neurological conditions [26, 27], and specific neuro-
degenerative diseases [28–30], the same image-guided CED 
platform has been increasingly called upon in testing CNS 
gene therapy strategies, including two ongoing Parkinson’s 
Disease (PD) trials [31, 32]. 
In this review, we will focus on the implications related to 
these specific PD gene therapies, and gene therapies utilising 
similar delivery platforms for other selected neurodegenerative 
conditions.
State of the art
Although the aetiopathogenesis of most idiopathic neuro-
degenerative disorders is likely to be due to a combination of 
genetic predisposition and exposome-induced epigenetic mo-
dulation [33], the pathophysiological characteristics associated 
with the expressed clinical phenotype are well-documented 
and increasingly understood. Alpha (α)-synucleinopathies are 
specific neurodegenerative disorders in which aggregates of 
α-synuclein (α-syn) protein accumulate within neurons, nerve 
fibres, and glia, with clear evidence of an associated parenchy-
mal cell loss [34]. The three main types of α-synucleinopathies 
include PD, dementia with diffuse Lewy bodies (DLB), and 
multiple system atrophy (MSA). An important feature of 
these three neuropathologies is that differential neuronal and 
glial susceptibilities appear to dictate the eventual phenotypic 
manifestations and clinical course. PD has both idiopathic and 
familial/genetic forms, with the latter including mutations/ 
/alterations involving the SNCA, LRRK2, VPS-35, PARKIN, or 
PINK1 genes, among others [35]. 
 For this review related to gene therapy, we will focus pri-
marily on idiopathic PD treatment strategies, and introduce 
recent considerations for MSA. Unfortunately, the primarily 
genetic forms of PD have yet to be tested in CNS gene therapy 
trials.
The idiopathic form of PD is rare before the age of 50, its in-
cidence and prevalence progressively increasing after the age of 
60 and peaking around the age of 85, with a male:female ratio 
of 1.4:1.0 [36]. Nearly 1 million individuals live with PD in the 
United States (US) in 2020, and there are at least 8-10 million 
worldwide. Before diagnosis, prodromal PD patients will suffer 
from a variety of non-motor impairments, including loss or re-
duction in olfaction, sleep disturbances, constipation, urinary 
dysfunction, orthostatic hypotension, and depression [37]. At 
the onset of clinical PD, findings include asymmetric motor 
disturbances, usually tremor or hyper-rigidity, that gradually 
evolve to include the cardinal signs of TRAP (Tremor, Rigidity, 
Akinesia, and Postural instability) with disease progression. 
Approved treatments for PD have varied over the years but 
include both medical and surgical interventions, including but 
not limited to the use of levodopa (L-dopa), dopamine ago-
nists, stereotactic brain lesioning, and deep brain stimulation 
(DBS). Most recently, trials testing an anti-α-syn antibody have 
been initiated [38]. While DBS has provided a rational and 
efficacious symptomatic treatment option for TRAP-related 
clinical features, the use of DBS has been limited due in part 
to associated risks and complexities of surgical implantation, 
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Figure 1. Schematic differences between diffusion-based and convection-enhanced delivery methods within brain parenchyma. Both 
methods are currently being used to provide therapeutic agents to specific target volumes within the brain. 
Left: Diffusion-based drug delivery within brain parenchyma. The top left schematic depicts a typical relatively large bore injection cannula 
that allows rapid injection of infusate but is associated with relatively large and uncontrolled reflux along the cannula resulting from transient 
increase in local tissue pressure. The reflux limits the distribution (blue) of the infusion volume (Vi) within the target. Through diffusion (seve-
ral millimetres), the relatively small residual Vi retained within the target (blue) is able to marginally increase the total brain volume perfused 
by infusate (grey). Note the depicted insufficient coverage of the target volume. The dashed black line across the diffusion volume, at the tip 
of the injection cannula, represents the bottom left concentration schematic for diffusion-based delivery. The bottom left schematic portrays 
the therapeutic concentration of infusate (yellow area under the curve) based on distance from centre of Vi, with an overlay of the limits of Vi 
(blue) and diffusion (grey). Note the steep concentration drop to sub-therapeutic threshold levels within short distances from the centre of Vi. 
Right: Convection-enhanced delivery (CED) within brain parenchyma. The top right schematic portrays CED’s smaller bore, reflux-resistant, 
stepped cannula. The steps on the cannula limit reflux along the cannula track and improve distribution of infusate within the extracellular 
fluid spaces via bulk flow. Although reflux and distribution beyond the first step, proximal to the cannula tip, allows greater coverage of the 
target volume, the second step typically prevents reflux along the cannula outside the target. Extracellular bulk flow induced by CED of the 
Vi provides a significantly larger volume of distribution (Vd) than via diffusion. The dashed black line along the Vd, at the tip of the CED 
cannula, represents the bottom right concentration schematic for CED-based drug delivery. As depicted in the bottom right schematic, the 
therapeutic concentration of infusate (yellow area under the curve) with CED extends for centimetres from the centre of Vi, providing a larger, 
more homogenous concentration of the therapeutic agent within the Vi, up to the convection limit. To contrast the two delivery methods, the 
diffusion concentration curve is also depicted
device programming, and hardware/maintenance-related 
complications. In general, PD has a clinical course that extends 
over many decades. Effective therapeutic approaches differ 
based on the stage of disease progression. 
Within the brains of PD patients, the accumulation of 
aggregated α-syn protein occurs within at-risk nigrostriatal 
dopaminergic neurons (DANs) and is exemplified by the 
progressive loss of striatal (primarily putaminal) dopami-
nergic (DAergic) neurotransmission, dopamine (DA) levels, 
an imbalance in inhibitory and excitatory signalling to and 
from the striatum, and the eventual manifestation of the 
cardinal signs, with worsening disability over time [39]. Early 
nigrostriatal degeneration features loss of terminal DAergic 
dendrites and synapses, especially within the dorsolateral 
putamen, and progressive dysfunction and death of DAergic 
cell bodies (and their axons) within the substantia nigra pars 
compacta (SNpc), and to a lesser extent within the adjacent 
ventral tegmental area (VTA) [40]. 
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Up to 25% of all DANs within the SNpc are estimated to 
be lost during the five years prior to the clinical onset of PD 
motor features, with additional exponential losses (toward 
~80% DAN loss) over the subsequent 15–25 years [41]. PD 
features significant neurodegeneration within other important 
brainstem nuclei, including the dorsal motor nucleus of the 
vagus, the pedunculopontine nucleus, locus coeruleus, and 
raphe [42]. Associated noradrenergic and serotonergic losses, 
together with reduced DAergic expression in cerebrocortical 
regions (from VTA DAN losses), are likely to impact sleep, 
mood, and cognition in PD patients. Importantly, however, 
the direct and indirect striatonigral pathways, originating from 
medium spiny neurons of the putamen, appear to remain intact 
in PD [40], and play a critical role in specific gene therapy 
strategies, as described below.
MSA is a rare α-synucleinopathy and neurodegenerative 
disease characterised by clinically progressive combinations 
of dysautonomia, pyramidal signs, parkinsonism and/or 
cerebellar dysfunction. With a prevalence of 3–5 cases per 
100,000 population (a total of up to 16,500), MSA meets the 
criteria of being an orphan disease (a condition affecting 
< 200,000 individuals) within the US. The clinical features 
at presentation are variable, but most MSA patients are 
categorised by predominant motor signs and segregated 
into either parkinsonian (MSA-P) or cerebellar (MSA-C) 
subtypes. Variability within, and overlap between, these two 
phenotypes is not uncommon, particularly in the later sta-
ges of the disease [43]. MSA-P is more prevalent in Western 
countries, accounting for 60–80% of MSA cases, whereas 
MSA-C predominates in Japan [43, 44] and the rest of Asia. 
The rate of disease progression, from the onset of motor signs, 
is relatively rapid in MSA cases, with the development of ma-
jor disability within 3–5 years, death within 8–10 years, and 
individuals rarely surviving 15 years from diagnosis [45, 46]. 
Dysautonomia is an early and pervasive characteristic of both 
MSA subtypes, often appearing years before the onset of the 
motor dysfunction [47], and contributing significantly to the 
progressive disability. 
Severe and early-onset of dysautonomia is a predictor of 
an aggressive disease phenotype [48] and a poorer prognosis 
[43]. With dysautonomia, MSA patients commonly expe-
rience genitourinary, gastrointestinal, and thermoregulatory 
dysfunctions, all of which have limited therapeutic options. 
Sleep disturbances are also prevalent in both MSA subtypes, 
especially rapid eye movement (REM) sleep behavioural di-
sorder, occurring in 70–80% of MSA patients but in only 50% 
of idiopathic PD patients [46]. Like PD, the aetiopathogenesis 
of MSA remains unclear, despite disease severity being directly 
related to the extent and burden of α-syn accumulations within 
glial (oligodendroglial) cells. Glial cytoplasmic inclusions 
(GCIs), composed of aggregated α-syn and phosphorylated 
α-syn [49, 50], are found within affected oligodendroglia. 
Concentrations of GCIs are especially profound within the 
putamen and substantia nigra of MSA patients [49, 51–53]. 
One proposed mechanism for the associated neurodegenera-
tion seen in MSA is the loss of neurotrophic support of central 
catecholaminergic neurons, as evidenced by significant loss 
of GDNF protein in the frontal cortex and cerebellum [54], 
as well as within the putamen [55]. Oligodendroglia are a key 
source of growth factors [56], including the production of 
GDNF, which is critical for the maintenance of adult catecho-
laminergic neurons [57]. Putaminal levels of GDNF and DA 
are significantly reduced in autopsied MSA patients compared 
to controls [55]. Such reduced GDNF levels may either result 
from striatal GCIs impairing the function of intrinsic neuronal 
populations known to produce GDNF, or from a primary loss 
of GDNF production within the striatum that leads to the focal 
accumulation of GCIs. The nigrostriatal pathway physiology is 
significantly altered under both proposed mechanisms, with 
a reduction in striatal GDNF and its trophic influence on 
DAN terminals. In either case, the DAergic dendrites within 
the putamen respond to the low intrinsic levels of GDNF by 
becoming ‘sick but not dead’ [55], reducing local DA levels, 
until eventually degenerating due to lack of trophic support. 
Under such circumstances, nigrostriatal DAergic axons un-
dergo similar responses to reduced striatal or local oligoden-
droglial GDNF production. 
Finally, nigral DAergic neuronal somata may be negatively 
influenced by lack of local oligodendroglial GDNF support 
and/or the negative influences provided by degenerating axon 
terminals within the putamen. Such nigrostriatal dysfunction 
is believed to result in prominent parkinsonian clinical featu-
res, as noted especially in MSA-P. The loss of oligodendroglial 
neurotrophic support resulting from GCIs may not only 
suppress nigrostriatal DAergic function, therefore, but may 
negatively influence other central catecholaminergic networks 
(noradrenergic, serotonergic), providing a basis for the evol-
ving dysautonomia. There are currently no specific treatment 
options for MSA other than those directed toward temporary 
symptomatic relief.
Methods for replenishing the brain’s neurotrophic en-
vironment in PD with direct GDNF protein delivery have 
been translated to the clinic, since systemic administration 
was unsuccessful in crossing the BBB. Initial investigations 
featured the use of serial, monthly intracerebroventricular 
infusions of recombinant GDNF protein (rGDNF) of varying 
doses via an implanted catheter system [58]. This randomised, 
double-blind, placebo-controlled trial, evaluating escalating 
doses of rGDNF versus placebo, in 50 subjects treated for eight 
months, showed no therapeutic efficacy. Probably, this lack of 
efficacy resulted from rGDNF not reaching the intended target 
structures (putamen and/or substantia nigra) in effective levels 
when delivered within the CSF, and as shown in other intra-
cerebroventricular protein infusion studies [1], while activity 
of rGDNF was determined in subjects experiencing adverse 
events, especially at higher protein doses delivered. Almost 
concurrently, initial intraparenchymal rGDNF infusions for PD 
were tested [59]. Intraputaminal stereotactic delivery cannulas 
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delivered rGDNF continuously (0.01 μg rGDNF/μL infusate; 
10.8-14.4 μg rGDNF/putamen/day) over 12 months [60], 
or via an intermittent delivery protocol (0.02 μg rGDNF/μL 
infusate; 120 μg rGDNF/putamen/4 weeks) for 40 weeks [61]. 
Although the safety and tolerability of the delivered rGDNF 
within the brain parenchyma was confirmed, and early signs of 
efficacy were suggested, a more recent single-centre, randomi-
sed, double-blind, placebo-controlled trial and trial extension 
failed to meet the primary trial endpoint [61, 62]. The authors 
interpreted their results as suggesting a greater likelihood of 
rGDNF infusion efficacy in a proposed intermittent (single 
dose delivered every four weeks) delivery Phase 3 trial, by 
extending treatment and clinical assessment from baseline to 
80 weeks, and providing a higher rGDNF dose (up to 0.06 μg 
GDNF protein/μL infusate) [62].
The problem of demonstrating the efficacy of GNDF 
protein infusion in PD trials over nearly two decades has 
resulted in pessimism directed towards additional therapeutic 
investigations utilising GDNF for the treatment of PD. Despite 
the proposed changes to the protocol for their forthcoming 
rGDNF Phase 3 trial, we believe there might be other technical 
issues to consider, based on the described delivery protocol 
[61], that might ultimately affect the trial’s efficacy. 
First and foremost, the delivery of rGDNF within the 
putamen (and CNS), using either continuous or intermittent 
infusion methods, has yet to be confirmed using contrast co-
-infusion and real-time MRI. Without such confirmation, the 
degree of on-target distribution and cannula reflux cannot be 
accurately predicted. Importantly, a reflux-resistant cannula 
was not utilised in any of the rGDNF infusion studies to date. 
Although utilising 2mM gadolinium test infusions, and CED 
infusion rates [9], there is a lack of data confirming that the 
cannula systems and pumps used actually provide convective 
flow and distribution [60–62]. Additionally, intermittent 
intraparenchymal delivery of rGDNF is known to provide 
concentration peaks and an exponential drop-off to below 
baseline levels within days to a few weeks following admini-
stration [63]. A 4-week delivery strategy for rGDNF would be 
associated with significant periods of time with subthreshold 
neurotrophic levels. Finally, we and others strongly believe that 
effective Vd is highly dependent on the Vi delivered, especially 
when using CED. Based on known human putaminal volumes 
[64], the percentage coverage of the estimated putaminal 
volume, following a known Vi (in gene therapies and rGDNF 
infusion studies), with and without CED ([31, 32, 65–68], 
and clinicaltrials.gov: NCT00985517, NCT01621581, 
NCT01973543, NCT02418598, NCT03065192), suggest a Vi 
of ≥ 1,800 μL is required to achieve a ≥ 50% putaminal Vd 
(Fig. 2). Unless abnormal brain anatomy and physiology are 
present [69], such a Vi, if convected over 4–7 hours, has been 
well tolerated [31].
There is growing clinical evidence of viral vector-based 
gene therapy approaches for delivering beneficial transgenes 
to the brains of PD patients [70, 71]. After being effectively 
developed in animal models and eventually translated to the 
clinic, two primary viral vectors have proved most useful and 
safe, based on either the adeno-associated virus (AAV) [72] 
or lentivirus (Lenti) [73]. The AAV serotype 2 (AAV2) has 
a preferential affinity to neurons [15], raising its relevance 
when targeting putamen and other neuronal populations in 
the CNS, and limiting transduction of glia and other non-
-neuronal cells. Lenti vector tropism can be specifically engi-
neered through pseudotyping strategies [74]. Both AAV2 and 
Lenti vectors have been employed to deliver relevant genetic 
payloads for treating PD to the human putamen. Small- and 
medium-sized spiny GABAergic neurons, making up 95% of 
putaminal neuronal populations [75], are the primary targets 
of transduction for both AAV2 and Lenti vectors delivered 
within that subcortical structure. These neuron populations 
are not typically associated with degeneration in PD, but are 
affected in MSA-P where caudal and dorsolateral populations 
of putaminal medium spiny neurons are severely depleted [76]. 
AAV2 has also been used in PD trials in attempts to influ-
ence the subthalamic nucleus, caudate, and substantia nigra 
[70, 71]. Currently active putaminal enzyme replacement 
strategies for PD utilise either AAV2 or Lenti, based on the 
size of the genetic payload being delivered. AAV vectors are 
most effective in packaging single stranded transgenes of less 
than 5 kilobases (kb) [77], approximating the size of the wild 
type viral genome, while Lenti vectors permit packaging of 
nearly double the payload of AAV [78]. PD trials replacing 
depleted aromatic amino acid decarboxylase (AADC) alone 
have utilised AAV2 constructs (AAV2-AADC) [31, 66, 79, 80], 
while those using Lenti vectors have delivered a trio of 
transgenes coding for AADC, tyrosine hydroxylase (TH) 
and GTP-cyclohydrolase 1 (GCH1) to augment dopamine 
production [81]. Both approaches have focused on replacing 
lost dopamine production capacity seen in the latter stages of 
PD and allowing titration of putaminal dopamine levels by 
altering the amount of precursor medication (L-dopa) taken. 
Nonhuman primate parkinsonian models have shown strong 
AADC expression in transduced putamen, with 10-to-20- fold 
improvements in behavioural responses to L-dopa medication 
[82, 83]. Since inception, the AAV2-AADC gene therapy for 
PD has primarily utilised our iMRI CED platform to gradually 
increase the delivered Vi to enhance putaminal transduction 
volume [31, 80], and is now delivering up to 1,800 μL per pu-
tamen. Using the same AAV2-AADC therapeutic delivered via 
a larger Vi alone (see Fig. 2G vs Fig. 2H), was associated with 
improved clinical results [31]. Similar iterations and detailed 
assessments of the Lenti tricistronic vector deliveries are not 
yet available [81]. Both strategies are progressing towards 
later stage investigations for efficacy, having shown safety and 
tolerability over many years. 
A PD gene therapy abandoned in 2012, that attempted 
to suppress subthalamic nucleus (STN) activity with an 
AAV2 vector carrying the glutamic acid decarboxylase (GAD) 
gene (AAV2-GAD), provided clinical benefits that were no 
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CED — convection-enhanced delivery; iMRI — intraoperative magnetic resonance imaging; AAV2 — adeno-associated virus, serotype 2; 
NRTN — neurturin; AAV2-NRTN — AAV2 vector carrying the NRTN gene; AADC — aromatic amino acid decarboxylase; AAV2-AADC — AAV2 
vector carrying the AADC gene; NCT — national clinical trials number; GDNF — glial cell-derived neurotrophic factor; AAV2-GDNF — AAV2 
vector carrying the GDNF gene; rGDNF — recombinant GDNF protein
better than DBS [84, 85]. A recent analysis of brain scan data 
from these trials [86], however, has encouraged a company to 
acquire the rights to this therapeutic approach. Unfortunately, 
significant limitations exist in terms of the number of subjects 
analysed. This approach will probably require a costly Phase 
3 trial to provide evidence of efficacy. 
Two neurotrophic factor gene therapies delivered via 
AAV2 vectors have provided either neurturin (AAV2-NRTN) 
or glial cell-line derived neurotrophic factor (AAV2-GDNF) 
to subjects with PD. Additional AAV2-NRTN trials have 
been abandoned due to failure to meet primary endpoints in 
two double-blind placebo-controlled studies, both of which 
targeted the bilateral putamen and one of which also infused 
the substantia nigra [65, 87]. Importantly, the AAV2-NRTN 
trials confirmed the safety of delivering growth factors to the 
putamen and substantia nigra [88], pathologically confirmed 
transduction limits using small parenchymal delivered Vi, 
especially without CED and optimised delivery technologies 
[68, 89–91], and suggested evidence that neurotrophic fac-
tor gene therapy may be more effective in earlier than later 
PD stages [87, 92]. The remaining neurotrophic factor gene 
therapy trial results in advanced PD, using AAV2-GDNF in 
a Phase 1 open-label study (NCT01621581), were recently 
published [32]. All treated subjects tolerated their iMRI CED 
procedure and three escalating vector doses without significant 
adverse events. Importantly, all 13 subjects treated are now 
over 36 months and some over 60 months post-op, and show 
a) stability of their clinical motor exams and activities of daily 
living, b) stability of their levodopa-equivalent daily doses, and 
c) significant increases in their fluorodopa positron emission 
tomography (PET) imaging signals at the infusion sites, when 
comparing baseline to the 6- and 18-month treatment inter-
vals. The study had a Vi of 450 μL per putaminal target and was 
determined by iMRI to provide an average of 26% coverage. An 
upcoming Phase 1b trial (NCT04167540) for 12 PD subjects, 
due to start in 2020, will test lessons learned from previous 
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gene therapy investigations. The open-label Phase 1b trial will 
test earlier stage (n = 6) compared to moderate to advanced 
stages (n = 6) of PD, anticipating greater potential efficacy for 
GNDF effects in the former group compared to the latter, based 
on residual nigrostriatal DANs [41], and preclinical [93] and 
clinical [87, 92] opinions advanced. This trial will also test 
the highest ever approved dose of AAV2-GDNF vector, not 
tested in the Phase 1 trial due to limited putaminal coverage 
(26%) attained using that protocol, and distributing a simi-
lar Vi (up to 1,800 μL per putamen) with surgical methods 
(single occipital longitudinal trajectory spanning each puta-
men) [11, 94] currently preferred in the AAV2-AADC gene 
therapy study (NCT03733496) [31]. As mentioned earlier in 
this review, the specific AAV2-GDNF vector delivered to the 
putamen in previous and current PD trials avails itself of the 
persistent striatonigral projections and anterograde transport 
provided by that particular AAV2 vector. Such capabilities 
allow GDNF trophic support to the at-risk putaminal DAN 
terminals as well as the DAergic somata that are ‘sick but not 
dead’ within the SNpc. The more residual nigrostriatal DANs 
present, the more robust the GDNF-induced upregulation 
and sprouting [93].
Clinical implications
There are specific clinical implications related to novel 
treat ments for neurodegenerative diseases such as PD and 
MSA, as well as a hereditary paediatric orphan disease 
with a genetic defect tied to catecholaminergic deficiencies 
(AADC-deficiency; AADC-d) [95]. AAV2-AADC gene 
therapy for PD is on track to provide therapeutic relief and 
mitigation of specific clinical features in subjects that would 
also be candidates for DBS surgery. Both AAV2-AADC and 
DBS, however, are not likely to influence the progressively 
downhill course of PD’s nigrostriatal degeneration and moun-
ting therapeutic sequelae that increase disability and shorten 
the lifespan of those afflicted. AADC gene therapy, however, 
has provided evidence of the ability to restore DA production, 
and some clinical benefit, when coupled to peripheral substrate 
(L-dopa) administration. The utility of AADC gene therapy in 
PD has encouraged use in AADC-d, where widespread loss of 
central and peripheral catecholaminergic production due to 
a genetic defect results in loss of intracellular AADC enzyme 
function and significantly impaired newborns, children and 
a few adults. AAV2-AADC gene therapy is currently being 
tested for AADC-d by two treatment teams, with one team tar-
geting the putamen ([96]; NCT01395641 and NCT02926066) 
and the other focusing on the midbrain (NCT02852213). Both 
approaches are currently trying to restore DAergic tone in the 
afflicted children, and results remain preliminary at this point.
However, it is clear that additional measures will be 
required to replenish additional catecholaminergic centres 
within the CNS affected by this genetic defect. With regards 
to the upcoming PD trial set to test intermittent parenchymal 
delivery of higher doses of rGDNF over a longer time period, 
we anticipate limited efficacy due to: 1) a lack of documented 
infusate distribution and infusion reflux assessment by con-
trast co-infusion and real-time MRI; 2) the rapid exponential 
loss of infused rGDNF from the parenchyma resulting in 
subthreshold GDNF levels shortly after infusion and for 
a significant period prior to the subsequent (every four 
weeks) treatment; 3) the inability of rGDNF infused within 
the striatum to influence distal targets such as the SNpc 
DAergic somata; and 4) the predisposition to infection and 
mechanical problems associated with the required indwelling 
devices currently necessary for such chronic treatments. We 
project that using a single putaminal AAV2-GDNF gene 
therapy treatment for PD may obviate the need for chronic 
infusions of rGDNF. AAV2-GDNF gene therapy, using the 
verified delivery platform, has the capacity to restore con-
stitutive, higher than baseline, levels of parenchymal GDNF 
within the striatum, and through striatonigral anterograde 
transport of the AAV2-GDNF vector, to SNpc, as defined in 
animal models [63, 93, 97]. 
We expect that a single gene therapy procedure should 
provide life-long transduction of target cells, and parenchymal 
trophic factor expression, as has been noted over at least eight 
years in both non-human primates [97] and humans [68]. In 
an alternative to antibody-based α-syn clearance for human 
PD [38], rodent investigations [98] suggest that AAV2-GDNF 
vector reduced the α-syn deposit burden in substantia nigra 
of aged mice, signifying that gene therapy-derived GDNF 
might mitigate the underlying neuropathology seen in sy-
nucleinopathies like PD and MSA. Although MSA-P has yet 
to be treated, therapeutic intervention using AAV2-GDNF 
gene therapy is currently being considered. Although the 
parkinsonian motor features in PD and MSA-P may benefit 
from AAV2-GDNF putaminal gene therapy, it remains to be 
seen whether the many debilitating non-motor features will 
also show relevant responses to treatment. 
Current and future investigations will include assessment 
tools to determine beneficial responses in specific non-motor 
conditions.
Future directions
The variabilities inherent within human investigations 
in clinical medicine make predicting success for any novel 
therapy a foolhardy undertaking. 
With humility, however, we anticipate that efficacious 
GDNF gene therapy clinical trial results, for either or both 
PD and MSA, will significantly increase demand for such 
treatments worldwide. We and others [99] believe, however, 
that improving gene therapy vector delivery within the CNS 
remains essential for proper testing of therapeutic efficacy. 
Optimised delivery strategies, including CED contrast co-
-infusions, real-time iMRI, and using increased Vi, provide 
safe and effective distribution methodologies, but allow the 
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confirmation of target coverage and off-target distribution that 
may impact upon clinical results. 
Current neurosurgical manpower is less than 4,000 in the US 
[100] and approaches 50,000 worldwide [101], with markedly 
fewer individuals experienced in the methods and technologies 
described in this review. Addressing this shortfall will require 
the expansion of educational/training opportunities for current 
neurosurgeons (and neurologists), and the augmentation of 
tailored training programmes related to specific surgical and 
neurological management capabilities. Although both neurosur-
geons and neurologists currently train in a variety of neuromo-
dulation approaches, only a limited number of specialty training 
programmes provide trainees with the experience required to 
deliver safe and effective CED therapeutic interventions. Gene 
therapy methods to treat specific CNS disorders continue to 
evolve, with an emphasis on a) training and sufficient num-
bers of clinical providers, b) being guided by evidence-based 
medicine, and c) considering the development of Centres of 
Excellence to specifically advance such treatment opportuni-
ties. Such advances will be critical to the safe, efficacious, and 
standardised evolution of CNS gene therapies. 
The future of effective gene therapy treatments for PD, 
MSA-P, and other CNS conditions, will feature CED platforms 
that avail themselves of growing iMRI capabilities in medical 
universities and hospitals. Supplements to the future neurosur-
gical armamentarium in meeting increased demand for such 
treatments will feature robotics and advanced technologies in 
the operating room [102–104] and artificial intelligence (AI) 
[105, 106] to improve the practitioner’s accuracy and speed of 
clinical diagnoses, presurgical and surgical planning, outcome 
predictions, and overall management. 
We await the results of forthcoming clinical trials to imple-
ment these and other strategies, focusing on safety and efficacy 
measures as we seek to improve the clinical trajectories in neu-
rodegenerative and other CNS diseases with gene therapies. 
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